Sanofi's GLP-1 drug hits promising marks in PhIII diabetes trial

Sanofi-Aventis' GLP-1 diabetes drug lixisenatide impressed analysts with a solid set of top-line results demonstrating its effectiveness--in combination with the bestselling Lantus--for controlling blood sugar. Adding a daily injection of lixisenatide helped Type 2 diabetes patients who had trouble controlling the disease with basal insulin alone.

Analysts at Bryan, Garnier has already noted that the drug's primary value for Sanofi lies in a combo treatment with Lantus. As Bloomberg notes, Sanofi is lagging behind Eli Lilly and Novo Nordisk in developing a GLP-1 therapy that spurs the pancreas to produce more insulin.

"The results of this study show that lixisenatide once-daily in combination with basal insulin provides a significant reduction in A1C," said Sanofi R&D chief Marc Cluzel. "Adding lixisenatide, a new GLP-1 with a strong post-prandial glucose effect, to a basal insulin may offer patients a new treatment approach to better control glucose and prevent long-term complications."

Lixisenatide was originally developed by Denmark's Zealand Pharma from ingredients found in the spit of the Gila monster.

- here's the Zealand release

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.